Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dc25-1593 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of a Claims-Based Algorithm to Characterize Uptake of Continuous Glucose Monitoring Among Older Adults With Type 1 and Type 2 Diabetes Meeting Medicare Coverage Criteria From 2017 to 2019.
Diabetes Care
September 2025
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Differences in Lyme Disease Diagnosis among Medicaid and Medicare Beneficiaries, United States, 2016-2021.
Emerg Infect Dis
September 2025
Lyme disease is the most common vectorborne disease in the United States. Evidence suggests that persons from racial and ethnic minority groups experience more severe disease. We used a claims-based algorithm on data from 16 jurisdictions with high Lyme disease incidence to identify cases among 4 populations: Medicaid beneficiaries <18 and >19 years of age, and Medicare fee-for-service beneficiaries <65 and >65 years of age.
View Article and Find Full Text PDFReal-world change in annualized relapse rate and healthcare resource utilization following initiation of ofatumumab in people with multiple sclerosis.
Mult Scler Relat Disord
July 2025
Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, USA.
Background: Ofatumumab (OMB) is an FDA-approved CD20-directed monoclonal antibody with demonstrated efficacy in reducing incidence of relapse in multiple sclerosis (MS). Real-world data are needed to ascertain OMB's effectiveness in reducing relapse in a broader MS population and to assess whether clinical benefits of OMB translate into decreased healthcare resource utilization (HCRU). The current study utilized a large US administrative claims database to compare relapse and MS-related HCRU before and after initiation of OMB therapy in a real-world sample of people with MS.
View Article and Find Full Text PDFHigh-risk care management impact on Medicaid ACO utilization and spending.
Am J Manag Care
July 2025
Mass General Brigham, 399 Revolution Dr, Somerville, MA 02145. Email:
Objectives: States are experimenting with accountable care organization (ACO) contracts to slow Medicaid spending growth. There is limited information on how ACOs have impacted expenditures in Medicaid, which includes a relatively heterogenous population with less spending compared with Medicare. This study aimed to evaluate the impact of high-risk care management on spending and utilization within Massachusetts' largest Medicaid ACO.
View Article and Find Full Text PDFReal-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis.
J Comp Eff Res
August 2025
University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR 72202, USA.
Phosphorodiamidate morpholino oligomers (PMOs) are exon-skipping therapies administered through once-weekly intravenous infusions used to treat Duchenne muscular dystrophy (DMD). This study assessed treatment patterns among patients with DMD receiving PMOs using administrative claims data while accounting for limitations in claims data for these therapies. This study used Inovalon public and private closed claims data (1 June 2016-31 March 2024).
View Article and Find Full Text PDF